PLEKHA7, an Apical Adherens Junction Protein, Suppresses Inflammatory Breast Cancer in the Context of High E-Cadherin and p120-Catenin Expression
Authors:
- Lindy J. PenceLPLindy J. Pence
- Antonis KourtidisAKAntonis Kourtidis
- Ryan W. FeathersRFRyan W. Feathers
- Mary T. HaddadMHMary T. Haddad
- Sotiris SotiriouSSSotiris Sotiriou
- Paul A. DeckerPDPaul A. Decker
- Aziza NassarAziza Nassar
- Idris T. OcalIOIdris T. Ocal
- Sejal S. ShahSSSejal S. Shah
- Panos Z. AnastasiadisPAPanos Z. Anastasiadis
Open Access
- 28 January 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1275
Abstract
Inflammatory breast cancer is a highly aggressive form of breast cancer that forms clusters of tumor emboli in dermal lymphatics and readily metastasizes. These cancers express high levels of E-cadherin, the major mediator of adherens junctions, which enhances formation of tumor emboli. Previous studies suggest that E-cadherin promotes cancer when the balance between apical and basolateral cadherin complexes is disrupted. Here, we used immunohistochemistry of inflammatory breast cancer patient samples and analysis of cell lines to determine the expression of PLEKHA7, an apical adherens junction protein. We used viral transduction to re-express PLEKHA7 in inflammatory breast cancer cells and examined their aggressiveness in 2D and 3D cultures and in vivo. We determined that PLEKHA7 was deregulated in inflammatory breast cancer, demonstrating improper localization or lost expression in most patient samples and very low expression in cell lines. Re-expressing PLEKHA7 suppressed proliferation, anchorage independent growth, spheroid viability, and tumor growth in vivo. The data indicate that PLEKHA7 is frequently deregulated and acts to suppress inflammatory breast cancer. The data also promote the need for future inquiry into the imbalance between apical and basolateral cadherin complexes as driving forces in inflammatory breast cancer.Keywords
All Related Versions
Funding Information
- National Cancer Institute (P50 CA11620, R21 CA246233-01A1)
- National Institute of Neurological Disorders and Stroke (R01 NS101721-01A1)
- National Institute of General Medical Sciences (P20 GM130457-01A1)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK123704-01)
This publication has 40 references indexed in Scilit:
- Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherinPLOS ONE, 2013
- PLEKHA7 Is an Adherens Junction Protein with a Tissue Distribution and Subcellular Localization Distinct from ZO-1 and E-CadherinPLOS ONE, 2010
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentAnnals of Oncology, 2010
- Dynamic and Static Interactions between p120 Catenin and E-Cadherin Regulate the Stability of Cell-Cell AdhesionCell, 2010
- Adherens Junction: Molecular Architecture and RegulationCold Spring Harbor Perspectives in Biology, 2009
- Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancerNature Cell Biology, 2009
- Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancerAnnals of Oncology, 2007
- A novel role for p120 catenin in E-cadherin functionJournal of Cell Biology, 2002
- Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complexNature Cell Biology, 2002
- Persistent E-Cadherin Expression in Inflammatory Breast CancerLaboratory Investigation, 2001